Wire · operational-macro
Actimed Completes Enrollment in PROACT Trial of S-Pindolol With Semaglutide
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
Actimed Therapeutics has completed patient enrollment in the PROACT Phase 2a trial testing S-pindolol benzoate alongside and after semaglutide therapy to address muscle loss during weight management. The trial targets the unmet need of preserving lean mass while using GLP-1 drugs, with results expected to influence obesity treatment strategies.
This Wire brief sits within Fusion42's coverage of Longevity & Wellness, Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
You have a rare chance to tackle the biggest gap in GLP-1 weight loss: muscle loss during and after treatment. Actimed’s trial opening signals a new adjunct drug opportunity for obesity therapies that protect lean mass and improve patient long-term outcomes.
◆ Coverage
1 source · 24 Sep 2026
◆ Related on Wire
◆ Topics